Immunovant, Inc. Research And Development Expense

Quick Answer

Immunovant, Inc. reported Research And Development Expense of $101.81 million for the year ending 2022.

  • Immunovant, Inc. showed an increase of +48.4% in Research And Development Expense from 2021 to 2022.
  • This data is from Immunovant, Inc.'s annual report (Form 10-K), filed with the SEC on June 8, 2022.
  • XBRL data for this metric is available from 2019 to 2022 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 4 years of available data (2019 to 2022), Immunovant, Inc.'s Research And Development Expense has grown by 295.6%.
  • Historical annual values: Fiscal year 2022: $101.81 million | Fiscal year 2021: $68.60 million | Fiscal year 2020: $47.93 million | Fiscal year 2019: $25.73 million.
  • Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: